Neurology/CNS Phase 3 Deal Benchmarks (2026)

Median upfront of $515M with total deal values reaching $3.4B.

Median Upfront

$515M

Total Deal Value

$2.6B

Royalty Range

14.1%–21.7%

Territory Multiplier

Understanding Neurology/CNS Deal Benchmarks at Phase 3

Phase 3 Neurology/CNS licensing deals command a median upfront payment of $515M, with values ranging from $313M at the low end to $695M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.8B to $3.4B, with a median of $2.6B. Royalty rates for neurology/cns assets at this stage typically fall between 14.1% and 21.7% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2023	Takeda	Lundbeck	$100M	$800M	licensing
2022	Biohaven Pharmaceutical	Pfizer	$11.6B	$11.6B	acquisition
2020	GW Pharmaceuticals	Jazz Pharmaceuticals	$7.2B	$7.2B	acquisition
2022	Voyager Therapeutics	Neurocrine Biosciences	$165M	$1.7B	licensing
2025	Biogen	Sage Therapeutics	$220M	$1.2B	codevelopment
2021	Yumanity Therapeutics	Janssen	$25M	$500M	collaboration
2024	Voyager Therapeutics	Novartis	$120M	$1.3B	licensing
2024	AviadoBio	Astellas Pharma	$50M	$2.2B	option
2024	Aliada Therapeutics	AbbVie	$1.4B	$1.4B	acquisition
2024	Vesalius Therapeutics	GSK	$80M	$650M	collaboration

PRO

See All Comparable Deals

View 10 comparable Neurology/CNS transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 3 Neurology/CNS deals?

The median upfront payment for Phase 3 Neurology/CNS licensing deals is $515M, based on our analysis of comparable transactions. Values range from $313M for early-stage or less differentiated assets up to $695M for premium programs with strong clinical data or first-in-class mechanisms.

How does Global territory affect Neurology/CNS deal value?

Global rights carry a 1x multiplier relative to base deal economics. This means global neurology/cns deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 3 Neurology/CNS licensing?

Royalty rates for Phase 3 neurology/cns assets typically range from 14.1% to 21.7% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$32M upfront

Neurology/CNS · Preclinical · Global

$76M upfront

Neurology/CNS · Phase 1 · Global

$232M upfront

Neurology/CNS · Phase 2 · Global

$1.5B upfront

Neurology/CNS · Approved · Global

$721M upfront

Oncology · Phase 3 · Global

$901M upfront

Immunology · Phase 3 · Global

$1.2B upfront

Metabolic/Obesity · Phase 3 · Global

$283M upfront

Neurology/CNS · Phase 3 · US Only

Explore More

All Neurology/CNS Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Neurology/CNS · Phase 3

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Neurology/CNS Phase 3 Deal Benchmarks (2026). Retrieved from https://calculator.ambrosiaventures.co/data/neurology-phase-3-deals-global

HTML

<a href="https://calculator.ambrosiaventures.co/data/neurology-phase-3-deals-global">Neurology/CNS Phase 3 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$313M	$515M	$695M
Total Deal Value	$1.8B	$2.6B	$3.4B
Royalty Rate	14.1%	—	21.7%